Clinical Trials Logo

Age-Related Maculopathies clinical trials

View clinical trials related to Age-Related Maculopathies.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01494805 Completed - Clinical trials for Macular Degeneration

Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

AMD
Start date: December 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD). Patients will be randomized to receive one of two doses of rAAV.sFlt-1 or assigned to the control group.

NCT ID: NCT01024998 Completed - Clinical trials for Macular Degeneration

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Start date: January 11, 2010
Phase: Phase 1
Study type: Interventional

This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).

NCT ID: NCT01003691 Completed - Clinical trials for Macular Degeneration

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

Start date: August 5, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.

NCT ID: NCT00877032 Completed - Clinical trials for Macular Degeneration

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.

NCT ID: NCT00563979 Completed - Clinical trials for Age-Related Maculopathies

Enhancement of Macular Pigment Density by Oral Lutein Supplementation

EMPOLS
Start date: July 2007
Phase: N/A
Study type: Interventional

The primary objective of EMPOLS is an increase in macular pigment density (MPD) and contrast sensitivity (CS) after six months supplementation of oral non-compound ester Lutein 10 mg daily, contained in VitaluxPlus®.

NCT ID: NCT00051129 Completed - Clinical trials for Macular Degeneration

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).